You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

NEXICLON XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nexiclon Xr patents expire, and what generic alternatives are available?

Nexiclon Xr is a drug marketed by Athena and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in NEXICLON XR is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nexiclon Xr

A generic version of NEXICLON XR was approved as clonidine by DIFGEN PHARMS on August 18th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NEXICLON XR?
  • What are the global sales for NEXICLON XR?
  • What is Average Wholesale Price for NEXICLON XR?
Summary for NEXICLON XR
International Patents:21
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 3
Raw Ingredient (Bulk) Api Vendors: 69
Clinical Trials: 4
Patent Applications: 4,366
What excipients (inactive ingredients) are in NEXICLON XR?NEXICLON XR excipients list
DailyMed Link:NEXICLON XR at DailyMed
Drug patent expirations by year for NEXICLON XR
Recent Clinical Trials for NEXICLON XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of LouisvillePhase 4
Arthroplasty Foundation, Inc.Phase 4
Mihaela VisoiuN/A

See all NEXICLON XR clinical trials

Pharmacology for NEXICLON XR

US Patents and Regulatory Information for NEXICLON XR

NEXICLON XR is protected by two US patents.

Patents protecting NEXICLON XR

Modified release formulations containing drug-ion exchange resin complexes
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Clonidine formulation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Athena NEXICLON XR clonidine TABLET, EXTENDED RELEASE;ORAL 022500-001 Dec 3, 2009 RX No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Athena NEXICLON XR clonidine TABLET, EXTENDED RELEASE;ORAL 022500-002 Dec 3, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Athena NEXICLON XR clonidine TABLET, EXTENDED RELEASE;ORAL 022500-001 Dec 3, 2009 RX No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Athena NEXICLON XR clonidine TABLET, EXTENDED RELEASE;ORAL 022500-002 Dec 3, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NEXICLON XR

See the table below for patents covering NEXICLON XR around the world.

Country Patent Number Title Estimated Expiration
South Korea 101495146 ⤷  Sign Up
Denmark 2018160 ⤷  Sign Up
Denmark 2428205 ⤷  Sign Up
Canada 2645855 FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES) ⤷  Sign Up
European Patent Office 2428205 Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes) ⤷  Sign Up
Austria E536867 ⤷  Sign Up
Israel 194042 פורמולציות לשחרור שונה המכילות קומפלקסים של תרופה ורזין מחליף יונים (Modified release formulations containing drug-ion exchange resin complexes) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.